JG
EPZM

Jefferies Group’s Epizyme, Inc EPZM Stock Holding History

Jefferies Group’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-22,828
Closed -$199K – 2140
2021
Q1 		$199K Buy
22,828
+5,237
+30% +$54.2K ﹤0.01% 1360
2020
Q4 		$191K Buy
+17,591
New +$217K ﹤0.01% 1382
2020
Q3 		– Sell
-32,682
Closed -$525K – 1628
2020
Q2 		$525K Buy
32,682
+27,682
+554% +$483K 0.01% 906
2020
Q1 		$78K Buy
+5,000
New +$107K ﹤0.01% 1828
2019
Q4 		– Sell
-30,877
Closed -$458K – 3163
2019
Q3 		$318K Sell
30,877
-9,323
-23% -$118K ﹤0.01% 2150
2019
Q2 		$505K Buy
+40,200
New +$517K ﹤0.01% 1664
2019
Q1 		– Sell
-20,642
Closed -$127K – 2742
2018
Q4 		$127K Buy
+20,642
New +$158K ﹤0.01% 1929

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Jefferies Group's EPZM Position: Q2 2021 in Review

Jefferies Group sold out of Epizyme, Inc (EPZM) in Q2 2021, closing a stake of 22,828 shares — an estimated $199K sold.

Jefferies Group first reported a position in EPZM in Q4 2018 and held it in 7 quarters. The position peaked at $525K in Q2 2020. 127 funds tracked by Wall St. Rank hold EPZM as of Q2 2021.

  • Jefferies Group reported no remaining Epizyme, Inc position as of Q2 2021 after selling out during the quarter.
  • Jefferies Group sold 22,828 Epizyme, Inc shares in Q2 2021, an estimated $199K.
  • Jefferies Group first reported a position in Epizyme, Inc in Q4 2018 and held it in 7 quarters.
  • Jefferies Group's Epizyme, Inc position peaked at $525K in Q2 2020.
  • 127 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.